Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, …
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation …
Glenmark’s new drug candidate to undergo first-in-human trial for treatment of advanced solid tumors and lymphomas
Glenmark Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to begin …
